PRLD Stock Price
Prelude Therapeutics Incorporated
PRLD stock price is $3.23 (-9.27% on the day), giving Prelude Therapeutics Incorporated a market cap of $284.10M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
PRLD Stock Overview
- Price
- $3.23
- Previous close
- $3.56
- Open
- $3.50
- Market cap
- $284.10M
- P/E ratio
- -2.9
- 52-week range
- $1.16 - $6.83
- 1-year price target
- $9.00
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NGS
- MarketXLS Rank
- 37
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein, which along with SMARCA4 controls gene regulation through chromatin remodeling, which is in phase 1 clinical trial for the treatment of advanced or metastatic solid tumors; PRT7732, selective and orally bioavailable SMARCA2 degraders, which is in phase 1 multi-dose escalation trial for the treatment of advanced or metastatic solid tumors and; PRT2527, a Cyclin-dependent Kinase 9 inhibitor, which is in phase 1 dose-escalation and confirmation for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PRLD | $3.23 | -9.3% | 488.71K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Prelude Therapeutics Incorporated Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW